You are here: Industry Insights > novo

News List

No US launch until 2020 for Novo’s new haemophilia therapy pharmaphorum
February 21, 2019
The US regulator has approved Novo Nordisk’s long-acting therapy for haemophilia A, Esperoct, as the Danish pharma seeks to maintain its presence in an increasingly competitive sector of the drug market.
Novo Holdings invests in three more AMR biotechs pharmaphorum
January 23, 2019
Novo Holdings’ REPAIR Impact Fund, which helps fund companies tackling antimicrobial resistance (AMR), has announced three new investments....
Novo taps e-therapeutics for diabetes target discovery drive fiercebiotech
December 28, 2018
Novo Nordisk has enlisted e-therapeutics to support target discovery efforts at its recently-opened research center in Oxford, U.K. .....
Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline fiercebiotech
December 26, 2018
Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline....
GlaxoSmithKline, Incyte, Novo Nordisk SHARE pharmaceutical-technology
December 24, 2018
GlaxoSmithKline (GSK) and Pfizer have agreed to combine their consumer healthcare businesses with combined annual sales of £9.8bn ($12.7bn) and establish a joint venture (JV).....
Novo begins R&D tie-up with AI biotech e-Therapeutics pharmaphorum
December 13, 2018
Novo Nordisk has signed a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to find new therapies for type 2 diabetes.
Novo, Oxford Uni set to launch diabetes alliance and research labs pharmatimes
September 14, 2018
Novo Nordisk and the University of Oxford are poised to begin ground-breaking work on therapeutic targets for type II diabetes with new research facilities set to open next week.
Novartis, Novo, Glaxo and others hunker down as hurricane sweeps in fiercepharma
September 14, 2018
As Hurricane Florence bore down on the southeast today, drugmakers were taking steps to keep medicine supplies flowing and employees out of harms way.
Novo's semaglutide hits the mark in Phase 3 type 2 diabetes study pharmafile
August 22, 2018
Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of adult patients with type 2 diabetes and moderate renal impairment......
Novo makes another early-stage diabetes bet with Ziylo buy evaluate
August 21, 2018
Intensifying pricing pressure in diabetes has not put Novo Nordisk off going after new technologies. The group’s latest acquisition, the UK company Ziylo, could lead to the development of insulin that “switches off” when blood glucose levels are too low.

Previous page 1 2 3 4 Next page